18,410 prescriptions for Novo Nordisk’s oral weight-loss drug hit pharmacies in a single debut week, according to IQVIA tracking data. The Danish pharmaceutical giant has officially pulled ahead of Eli Lilly, whose rival drug Foundayo is suffering from what analysts call "weak early uptake." Shares in Eli Lilly fell 4% on Friday as demand momentum shifted toward Wegovy and Ozempic. The gap in market share is becoming a social chasm as much as a financial one.

President Donald Trump announced his administration negotiated a deal to sell these shots to Medicare for just $245 a month. This is a significant discount from their usual retail tags, effectively offering the public a cut-price entry into the subscription body club. While Eli Lilly works to expand its position, Novo Nordisk is recovering toward the upper end of its trading band. The war for the global waistline is currently being won by the Danes.

For our readers, this is the metabolic velvet rope in action. While the pedestrian masses can now access the $245-a-month version, the truly bespoke results remain a high-cost luxury. The culling of "pedestrian medicine" has begun. If you aren't on the right prescription, you simply aren't in the winners' circle. The data doesn't lie: people are choosing their injectable lifestyle with the same care they use for their car leases.